



January 16, 2026

To whom it may concern

Company name: TAKASAGO INTERNATIONAL CORPORATION
Name of representative: Satoshi Masumura
President and Chief Executive Officer
(Securities code: 4914; TSE Prime Market)
Inquiries: Hiroyasu Hirata, General Manager, Corporate Administration Div.
(Telephone: +81-03-5744-0523)

Notice Concerning Acceptance of Tender Offer and (Expected) Recording of Extraordinary Income

TAKASAGO INTERNATIONAL CORPORATION (the “Company”) hereby announces that, at its Board of Directors meeting held today, it resolved to accept a tender offer made by TAIYO KOSAN CO., INC. (the “Tender Offer”) for all of the common shares of Hisamitsu Pharmaceutical Co., Inc. (securities code: 4530) held by the Company, and that, upon acceptance, in the event that the Tender Offer is consummated, it expects to record an extraordinary income in the fiscal year ending March 31, 2026, as a gain on sales of investment securities.

1. Reason for accepting the Tender Offer
The Company holds shares of Hisamitsu Pharmaceutical Co., Inc. as cross holdings. After reviewing the details of the Tender Offer, the Company decided to accept the Tender Offer, based on the facts such as that the Board of Directors of Hisamitsu Pharmaceutical Co., Inc. has expressed its approval and the terms and conditions of the purchase price, etc. are determined to be reasonable.
2. Number of shares to be tendered in the Tender Offer
Number of shares held before the Tender Offer: 420,534 shares
Number of shares to be tendered: 420,534 shares
Number of shares held after the Tender Offer: 0 shares
3. Planned purchase price in the Tender Offer
6,082 yen per common share (planned total sales amount: 2,557 million yen)
4. Time schedule of the Tender Offer
Date of the public announcement of the commencement of the tender offer: January 7, 2026
Tender offer period: from January 7, 2026 to February 19, 2026
Date of payment commencement: February 27, 2026
5. Future outlook
The Company expects to record a gain on sales of investment securities of 2,408 million yen in its individual and consolidated financial statements for the fiscal year ending March 31, 2026, if the Tender Offer is completed at the planned purchase price and all of the shares of Hisamitsu Pharmaceutical Co., Inc. held by the Company are sold.

Note: This document has been translated from the Japanese original for reference purposes only. In the event of any discrepancy between this translated document and the Japanese original, the original shall prevail.